Biologics and Biosimilars Landscape 2025: IP, Policy, and Market Developments

Why It Matters

These developments accelerate biosimilar entry, compress pricing, and reshape patent‑dance strategies, impacting payer costs and patient access across the biologics market.

Key Takeaways

• FDA approved 18 biosimilars across six therapeutic areas in 2025
• Interchangeable designations rose to over 20, easing market entry
• Denosumab and aflibercept litigations dominate BPCIA lawsuits
• Draft FDA guidance aims to drop comparative efficacy trials

Pulse Analysis

The U.S. biosimilar landscape in 2025 demonstrated robust expansion, with 18 new approvals covering oncology, immunology, ophthalmology, bone health, diabetes, and supportive care. Interchangeable designations more than doubled, reflecting the FDA’s intent to lower barriers for substitution. A crowded denosumab pipeline and the debut of interchangeable pertuzumab and omalizumab products illustrate how manufacturers are targeting high‑volume biologics, promising greater competition and potential price reductions for insurers and patients.

Legal pressures intensified as BPCIA lawsuits clustered around high‑revenue reference products. Amgen’s six new complaints on denosumab and Regeneron’s ongoing aflibercept MDL underscore the strategic use of patent‑dance tactics to delay biosimilar launches. Simultaneously, PTAB activity surged, with 18 inter‑ partes reviews and 13 post‑grant reviews, notably challenging manufacturing‑process patents and keytruda® enzyme technology. Antitrust suits, such as Regeneron v. Amgen, further highlight the contentious intersection of patent law and market competition in the biologics arena.

Regulatory and policy shifts are poised to reshape the market trajectory. Draft FDA guidance proposes eliminating default Phase III comparative efficacy trials, relying instead on analytical and PK data, which could shorten development timelines. Legislative proposals—including the Drug Competition Enhancement Act and the Biosimilar Red Tape Elimination Act—aim to curb product‑hopping and streamline interchangeable status. Coupled with the Inflation Reduction Act’s emerging Medicare price‑negotiation framework, these changes suggest a future where biosimilars achieve faster market entry, tighter pricing, and broader patient access, while legal and regulatory stakeholders adapt to a more streamlined yet still contested environment.